ASCIA Submissions 2022

  • ASCIA letter to Medical Services Advisory Committee (MSAC) in support for the Human Genetics Society of Australasia (HGSA) application for services provided by genetic counsellors, submitted on 7 October 2022.
    pdfASCIA supports HGSA MSAC application 20221007
  • ASCIA letter to PBAC supporting the PBS listing of PBS Nucala® (mepolizumab) for treatment of nasal polyps in chronic rhinosinusitis, submitted on 20 September 2022.
    pdfASCIA letter PBAC Nucala 2022092069.78 KB Nucala® (mepolizumab) is now subsidised by the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023 as an add-on treatment for adult patients (18 years and above) with chronic rhinosinusitis with nasal polyps (CRSwNP) that is severe, eosinophilic and recurrent post-surgery.. Read more here
  • Joint letter to the federal Health Minister, the Hon Mark Butler MP, regarding pricing of medical nutrition products for cow’s milk allergy has been sent on behalf of ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Strategy, submitted on 28 July 2022.
  • Letters from ASCIA supporting research project appications to the Medical Research Future Fund (MRFF) have been submitted on 16 February, 3 March, 16 May, 24 June and 1 July 2022.
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a SCID-ADA patient, in response to a request sent to ASCIA on 8 July 2022. Lodged 20 July 2022. 
  • ASCIA submitted responses to a survey on the Consultation Draft - National Medicines Policy. Lodged 2 March 2022. 
  • Letter from ASCIA in support of the application to the PBAC for PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis (eczema) in children aged 6-11 years. Lodged 13 January 2022.
    pdfASCIA letter PBAC Dupilumab 2022 01 1352.73 KB
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a patient with DiGeorge Syndrome and Severe Combined Immune Deficiency (SCID), in response to a request sent to ASCIA on 4 January 2022. Lodged 12 January 2022. 

 

Mod ASCIA Member
Donate to AIFA
go to NAC website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia